Lin BioScience, Inc. (TPEX:6696)
Taiwan · Delayed Price · Currency is TWD 731.00
+27.00 (3.84%)
Aug 6, 2026, 9:20 AM CST
Lin BioScience Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,363 | -744.27 | -687.19 | -313.52 | -434.7 |
Depreciation & Amortization | 22.97 | 20.05 | 17.93 | 11.16 | 4.39 |
Other Amortization | 0.82 | 0.16 | - | - | - |
Loss (Gain) From Sale of Assets | - | - | - | - | -0.22 |
Loss (Gain) From Sale of Investments | - | -1.57 | - | - | - |
Stock-Based Compensation | 1,204 | 291.06 | 115.15 | 44.39 | 8.91 |
Other Operating Activities | -1,417 | -638.24 | -378.32 | -105.16 | 105.77 |
Change in Accounts Receivable | -1.96 | 25.07 | -25.02 | 1.46 | -1.48 |
Change in Accounts Payable | 127.53 | 8.36 | 60.64 | 13.32 | 19.46 |
Change in Other Net Operating Assets | -14.79 | 20.08 | -116.02 | -12.66 | 8.02 |
Operating Cash Flow | -1,441 | -1,019 | -1,013 | -361.01 | -289.84 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -7.2 | -5.82 | -1.97 | -22.38 | -2.12 |
Sale of Property, Plant & Equipment | - | - | - | - | 0.51 |
Sale (Purchase) of Intangibles | -0.97 | -1.53 | - | - | - |
Investment in Securities | -9,534 | -3,612 | - | - | - |
Other Investing Activities | 178.1 | 68.2 | 3.83 | -1.67 | 0.13 |
Investing Cash Flow | -9,364 | -3,551 | 1.87 | -24.06 | -1.48 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | -16.42 | -14.63 | -11.86 | -5.53 | -2.91 |
Net Debt Issued (Repaid) | -16.42 | -14.63 | -11.86 | -5.53 | -2.91 |
Issuance of Common Stock | 755.59 | 98.38 | 622.41 | 511 | 31.23 |
Other Financing Activities | 19,742 | 2,581 | 2,026 | 624.32 | - |
Financing Cash Flow | 20,481 | 2,665 | 2,637 | 1,130 | 28.32 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 744.13 | 132.64 | -10.14 | 93.66 | -22.41 |
Net Cash Flow | 10,420 | -1,773 | 1,616 | 838.39 | -285.4 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,449 | -1,025 | -1,015 | -383.4 | -291.96 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Per Share | -17.64 | -13.04 | -13.72 | -5.34 | -4.24 |
Levered Free Cash Flow | -458.28 | -573.21 | -635.88 | -658.48 | -31.55 |
Unlevered Free Cash Flow | -457.68 | -572.58 | -635.13 | -657.93 | -31.5 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 1.02 | 1 | 1.21 | 0.88 | 0.07 |
Cash Income Tax Paid | -54.69 | -69.4 | -29.53 | -18.4 | -9.53 |
Change in Working Capital | 110.78 | 53.51 | -80.39 | 2.12 | 26.01 |